The role of maintenance treatment in advanced non-small-cell lung cancer: reality or early second line?
作者： Cesare Gridelli , Antonio Rossi , Paolo Maione , Rita Ambrosio , Valentina Barbato
关键词:
摘要: Abstract First-line platinum-based chemotherapy has reached a plateau of effectiveness for the treatment patients with advanced non–small-cell lung cancer (NSCLC). In who reported stable disease, no more than 4 cycles are recommended while maximum 6 is in responding to therapy. A potential strategy aim improving outcomes NSCLC administer This term includes different approaches: duration therapy, sequential consolidation and maintenance Here, we attempt define approaches that fall under rubric strategy, discuss results available date.
metapress.com参考文章(32)
Koji Takeda, Toyoaki Hida, Tosiya Sato, Masahiko Ando, Takashi Seto, Miyako Satouchi, Yukito Ichinose, Nobuyuki Katakami, Nobuyuki Yamamoto, Shinzoh Kudoh, Jiichiro Sasaki, Kaoru Matsui, Koichi Takayama, Tatsuhiko Kashii, Yasuo Iwamoto, Toshiyuki Sawa, Isamu Okamoto, Takayasu Kurata, Kazuhiko Nakagawa, Masahiro Fukuoka, Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203) Journal of Clinical Oncology. ,vol. 28, pp. 753- 760 ,(2010) , 10.1200/JCO.2009.23.3445
Rabab M Gaafar, Veerle F Surmont, Giorgio V Scagliotti, Rob J Van Klaveren, Demetris Papamichael, John J Welch, Baktiar Hasan, Valter Torri, Jan P van Meerbeeck, EORTC Lung Cancer Group, A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03) European Journal of Cancer. ,vol. 47, pp. 2331- 2340 ,(2011) , 10.1016/J.EJCA.2011.06.045
V. Westeel, E. Quoix, D. Moro-Sibilot, M. Mercier, J.-L. Breton, D. Debieuvre, P. Richard, M.-A. Haller, B. Milleron, D. Herman, M.-C. Level, F.-X. Lebas, M. Puyraveau, A. Depierre, , Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non–Small-Cell Lung Cancer Journal of the National Cancer Institute. ,vol. 97, pp. 499- 506 ,(2005) , 10.1093/JNCI/DJI096
_ _, Non–Small Cell Lung Cancer Journal of The National Comprehensive Cancer Network. ,vol. 6, pp. 228- 269 ,(2010) , 10.6004/JNCCN.2008.0021
M. Perol, C. Chouaid, B. J. Milleron, R. Gervais, F. Barlesi, V. Westeel, J. Crequit, H. Lena, A. Vergnenegre, D. Pérol, Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study. Journal of Clinical Oncology. ,vol. 28, pp. 7507- 7507 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.7507
C. P. Belani, D. M. Waterhouse, H. Ghazal, S. S. Ramalingam, R. Bordoni, R. Greenberg, R. M. Levine, J. M. Waples, Y. Jiang, G. Reznikoff, Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 28, pp. 7506- 7506 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.7506
R. M. Gaafar, V. Surmont, G. Scagliotti, R. Van Klaveren, D. Papamichael, J. Welch, B. Hasan, V. Torri, J. P. Van Meerbeeck, A double-blind, randomized, placebo-controlled phase III intergroup study of gefitinib (G) in patients (pts) with advanced NSCLC, non-progressing after first-line platinum-based chemotherapy (EORTC 08021-ILCP 01/03). Journal of Clinical Oncology. ,vol. 28, pp. 7518- 7518 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.7518
Goldie Jh, Coldman Aj, A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer treatment reports. ,vol. 63, pp. 1727- 1734 ,(1979)
Ian E. Smith, Mary E.R. O’Brien, Denis C. Talbot, Marianne C. Nicolson, Janine L. Mansi, Tamas F. Hickish, Alison Norton, Susan Ashley, Duration of Chemotherapy in Advanced Non–Small-Cell Lung Cancer: A Randomized Trial of Three Versus Six Courses of Mitomycin, Vinblastine, and Cisplatin Journal of Clinical Oncology. ,vol. 19, pp. 1336- 1343 ,(2001) , 10.1200/JCO.2001.19.5.1336
F. F. Kabbinavar, V. A. Miller, B. E. Johnson, P. G. O'Connor, C. Soh, , Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. ,vol. 28, pp. 7526- 7526 ,(2010) , 10.1200/JCO.2010.28.15_SUPPL.7526